213results about "Interferons" patented technology

The present application provides, in part, pharmaceutical formulations of Clec9A-based chimeric protein complexes and uses thereof.

Provided are methods of diagnosis and treatment of atopic dermatitis.

Disclosed herein are porcine interferon alpha variants (pINF-α) comprising a synthetic amino acid at select locations in pINF-α and a one or two amino acid insertion in the N-terminus after removal of the signal peptide. The pINF-α variants can further be pegylated. Methods of making and administering these compounds to treat virus infections in pigs and formulations comprising the variants are also provided.

Disclosed herein is a method for treating human chronic Hepatitis B virus infection by reducing or eliminating cccDNA in liver cells of HBV-infected patients for three months or more.

The application discloses a preparation method of a recombinant ternary fusion protein dressing with epidermal cell activation function. The dressing is a fusion protein designed based on the research on the functions and properties of COL3A1 and IFN-kappa proteins by international peers and the laboratory. The specific method is that the fusion gene fragment of the covalent connection of COL3A1 and IFN-kappa with GGSGG as a linker is obtained by using overlap extension PCR technology, and a 6×His label is added. The target gene is cloned into a prokaryotic expression vector pET30 (modified in the laboratory) to obtain the fusion protein COL3A1-IFN-kappa with an MBP label. After expansion culture, the MBP-IFN-kappa-COL3A1 with a purity of more than 90% can be obtained through Ni-NTA column affinity chromatography. We verified the resistance of the fusion protein to salmonella in THP-1 cells, and verified the effect of the fusion protein on promoting wound healing and resisting salmonella infection on mice. Finally, it is proved that the MBP-IFN-kappa-COL3A1 has good uniformity, is easy to purify, has high activity, has no side effects, and is very suitable for being used as an epidermal cell activation dressing.

The present invention relates to agents, compositions, and methods for treating or ameliorating symptoms of cancer. Exemplary synergistic therapies include the use of antisense oligonucleotide agents to suppress expression of TGF-β2, alone and in combination with interferon-gamma. One or more biomarkers can be used to select subjects for treatment.

This invention relates to proteins and peptides comprising a single immunoglobulin variable domain (ISVD) fused with a cytokine, belonging to the field of immunology. In particular, the invention provides a chimeric protein comprising a single immunoglobulin variable domain (ISVD) fused with a cytokine, wherein the internal fusion site of the ISVD is linked to the cytokine and the internal fusion site is located within a loop or turn between two secondary structural elements. Fusion of the cytokine to the ISVD upon binding of the cytokine to a receptor or receptor subunit enables the regulation of cytokine receptor activity and / or downstream signaling.

This disclosure relates to methods for treating a person having chronic hepatitis B. These methods comprise administering a therapeutically effective amount of antisense oligonucleotide (ASO) (e.g., bepirovirsen) and a therapeutically effective amount of interferon to a person in need, who has a baseline HBsAg level below the threshold level. This disclosure further relates to specific dosing regimens.

The instant disclosure is directed to polymer engineered forms of interferon- gamma (IFN-γ) cysteine mutein compounds, compositions comprising the compounds, and related methods and uses, for example, in the treatment of conditions responsive to therapy with IFN-γ.

Provided herein are novel constructs comprising gold nanoparticles bound to two types of cytokines, wherein the two types of cytokines comprise Tumor Necrosis Factor alpha (TNF ) and a cytokine selected from the group consisting of Interferon gamma (IFN ) and lnterleukin-12. Further provided is a method for treating cancer in a subject in need thereof.

The disclosure provides for recombinantly modified Zika-based vectors that can be used in gene therapy applications.

The invention provides modRNA (Ribonucleic Acid) for treating obliterated bronchitis, and belongs to the technical field of bioengineering. The modRNA for treating obliterated bronchitis provided by the invention is composed of an IL-10 modRNA (Interleukin-10) and an IFN (Interferon)-alpha modRNA (Interferon-alpha) modRNA. The BO treatment effect is achieved by inhibiting bronchial epithelial cell epithelial-mesenchymal transition (EMT), the expression of alpha-SMA and Vimentin in lung tissue can be remarkably reduced, the expression of E-cadherin and Cytokeratin 5 can be up-regulated, microbronchial epithelial injury is repaired, collagen deposition is reduced, and the lung function is improved. The synergistic effect of the two is better than that of single gene therapy, the safety is high, and the controllability is strong.

Provided are a fusion protein, a preparation method therefor and the use thereof. The fusion protein contains a His tag, a SUMO tag, and natural canine interferon-α, wherein the His tag has an amino acid sequence as represented by SEQ ID NO: 11, the SUMO tag has an amino acid sequence as represented by SEQ ID NO: 12, and the natural canine interferon α has an amino acid sequence as represented by SEQ ID NO: 7. The fusion protein exhibits an extremely significant increase in expression level and yield, has preparation stability and biological activity significantly greater than those of a native canine interferon-α protein, and has good safety.

Providing a CDKN2a companion diagnostic for interferon therapy for bladder cancer. [Solution] A method for treating bladder cancer, comprising the steps of: diagnosing bladder cancer in a human; measuring the CDKN2A expression level in the human; and subsequently injecting an interferon expression-inducing agent into the human. Non-muscle-invasive bladder cancer (NMIBC) represents the most common disease state in patients with newly diagnosed bladder cancer. Those with high-grade (HG) tumors are at significant risk of both recurrence and progression.

This application provides, in part, pharmaceutical formulations of Clec9A-based chimeric protein complexes and their uses.

A composition and a new method of manufacturing and producing such composition including modified interferon alpha 2 b, modified acetylated interferon alpha 2 b, and / or a mixture thereof is disclosed herein.

In certain aspects, the disclosure relates to a nucleic acid molecule encoding two or more different thanotransmission polypeptides. Thanotransmission is communication between cells that is a result of activation of a cell turnover pathway in a target cell, which signals a responding cell to undergo a biological response. Vectors (e.g., engineered viruses, plasmids and transposons), cells and pharmaceutical compositions comprising one or more nucleic acid molecules encoding two or more thanotransmission polypeptides are also disclosed. Methods of promoting thanotransmission by a target cell, methods of promoting an immune response in a subject, and methods of treating cancer in a subject are further disclosed.

The present invention provides fusion proteins comprising human IFN-[alpha] 2, a first antigen-binding domain capable of binding to human PD-L1, a second antigen-binding domain capable of binding to human PD-L1 and to human IFN-[alpha] 2, and methods of using the same.

This invention relates to agents, uses, and methods for treating cancer with synergistic therapeutic strategies involving one or more agents for suppressing expression of TGFB2, IRF9, LGALS9, and IFI27, along with guiding use of tumor-associated biomarkers. The agents and compositions can be used in combination with chemotherapy and other standard-of-care therapies.

Artificial expression constructs including a PD1:cytokine chimera transgene under the control of an inducible promoter are described. The artificial expression constructs can be used to enhance the function of a recombinant receptor-immune cell (e.g., CAR-T cell). The inducible PD1:cytokine chimera transgenes disclosed herein enhance the potency of the recombinant receptor-immune cell (e.g., CAR-T cell), resulting in potentiated killing, immune cell proliferation, and / or cytokine output.

The present invention relates to a fusion protein comprising at least two cytokines, of which at least one is a modified cytokine with a strongly reduced binding affinity to its receptor, or to one of its receptors. Preferably, both cytokines are connected by a linker, preferably a GGS linker. The invention relates further to said fusion protein for use in treatment of diseases.

Described herein are nucleic acids and recombinant viral vectors comprising the nucleic acids, where the nucleic acids encode a payload of interest (e.g., interferon).

Provided are masked interferon fusion proteins that is cleavable to release human type 1 interferon (IFN) polypeptide. In various examples, the masked interferon fusion proteins include a masking moiety, an IFN polypeptide, a cleavable linker connecting the masking moiety and the IFN polypeptide and an Ig Fc region that is linked to the IFN polypeptide. Methods of using the same for treating cancer and autoimmune disease or inflammatory condition are also provided. Also provided herein are interferon masking moieties that bind to human IFN and the uses for inhibiting IFN activity thereof.

The application relates to a dual cytokine fusion protein composition, pharmaceutical composition, and / or formulation thereof comprising the alpha and beta multi-subunits cytokines, such as IL-12 or IL-27, fused to a single chain variable fragment scaffolding system and a second cytokine, where the second cytokine is linked in the hinge region of the scFv. The application also relates to methods of using the dual cytokine fusion protein composition for treating cancer, inflammatory diseases or disorders, and immune and immune mediated diseases or disorders.

The presently disclosed subject matter relates to tumor infiltrated T cells induced by oncolytic virus ("OV-induced T cells"), methods of making and using said OV-induced T cells for an adoptive T-cell therapy. The presently disclosed subject matter further relates to oncolytic viruses and armed oncolytic viruses, methods of making and using said oncolytic viruses, as well as pharmaceutical compositions and kits comprising said oncolytic viruses.

A linker for linking a therapeutic agent to another moiety, such as the Fc region of an antibody. A linker having two or more maleimide functional groups capable of undergoing a nucleophilic conjugate addition reaction. A method for increasing the duration of action of a therapeutic agent by conjugating it to a novel linker and the Fc region of an antibody. An antibody-drug conjugate having an increased duration of action over the drug alone.

Provided are methods of preparing engineered and non-engineered Vδ1 T cells and uses thereof. The Vδ1 T cells are useful in the treatment of various cancers, infectious diseases, and immune disorders. Also provided are methods for expanding engineered and non-engineered Vδ1 T cell populations to therapeutically useful quantities. An engineered Vδ1 T cell can be a universal donor, and can be administered to a subject with any MHC haplotype.

The present invention relates, in part, to chimeric proteins comprising a modified human IFN-γ having one or more mutations that confer reduced affinity and / or biological activity that is restorable by attachment to one or more targeting moieties. The one or more targeting moieties may have recognition domains which specifically bind to antigens or receptors of a tumor or an immune cell. The one or more recognition domains may be a single-domain antibody or a single-chain antibody (scFv). The application also provides use of the chimeric proteins as therapeutic agents.